Autoimmunity and infection in Sjögren's syndrome

Current Opinion in Rheumatology

Volumn 25, Issue 4, 2013, Pages 480-487

  Igoe, Ann ^a,b,c   Scofield, R Hal ^a,b,c  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

autoimmunity; infection; Sjogren's syndrome; virus

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; AROMATIC HYDROCARBON RECEPTOR; AUTOANTIBODY; DIOXIN; INTERFERON; RECOMBINANT INTERFERON;

AUTOIMMUNITY; BETAHERPESVIRINAE; COXSACKIE VIRUS; COXSACKIE VIRUS INFECTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN PARVOVIRUS B19; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MOLECULAR MIMICRY; MUROMEGALOVIRUS; NONHUMAN; PATHOGENESIS; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SEROLOGY; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS INFECTION; VIRUS REPLICATION; VIRUS STRAIN;

AUTOIMMUNITY; HUMANS; SJOGREN'S SYNDROME; VIRUS DISEASES;

EID: 84879882358     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32836200d2     Document Type: Review

References (95)

1. Theander A, Wollheim FA. A note from Sweden: Recollection of Henrik Sjogren. In: Fox RI, Fox CM, editors. Sjogren's Syndrome: Practical Guidelines to Daignosis and Therapy. New York: Springer; 2012. pp. 11-13.
2. Shiboski SC, Shiboski CH, Criswell LA, et al. American College of Rheumatology classification criteria for Sjogren's syndrome: a data-driven, expert consensus approach in the Sjogren's International Collaborative Clinical Alliance Cohort. Arthritis Care Res 2012; 64:475-487.
3. Moutsopoulos HM. Sjogren's syndrome or autoimmune epithelitis? Clin Rev Allergy Immunol 2007; 32:199-200.
4. Haga H, Naderi Y, Moreno AM, et al. A study of the prevalence of sicca symptoms and secondary Sjogren's syndrome in patients with rheumatoid arthritis, and its association to disease activity and treatment profile. Int J Rheum Dis 2012; 15:284-288.
5. Haugen AJ, Peen E, Hultén B, et al. Estimation of the prevalence of primary Sjogren's syndrome in two age-different community-based populations using two sets of classification criteria: the Hordaland Health Study. Scand J Rheumatol 2008; 37:30-34.
6. Jarvinen P, Aho K. Twin studies in rheumatic diseases. Semin Arthritis Rheum 1994; 24:19-28.
7. Selmi C, Mayo MJ, Bach N, et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology 2004; 5085:485-492. (Pubitemid 39091897)
8. Fox RI, Fox CM. Sjogren's syndrome: infections that may play a role in pathogenesis, mimic the disease, or complicate the patient's course. Indian J Rheumatol 2011; 6:13-25.
9. Nakamura H, Takagi Y, Kawakami A, et al. HTLV-I infection results in resistance toward salivary gland destruction of Sjogren's syndrome. Clin Exp Rheumatol 2008; 26:653-655.
10. Chen M-H, Hsiao L-T, Chen M-H, et al. Clinical significance of chronic hepatitis B virus infection in patients with primary Sjogren's syndrome. Clin Rheumatol 2012; 31:309-315.
11. Sipsas NV, Gamaletsou MN, Moutsopoulos HM. Is Sjogren's syndrome a retroviral disease? Arthritis Res Ther 2011; 13:212.
12. Bach J-F. Infections and autoimmune diseases. J Autoimmun 2005; 25 (Suppl.):74-80. (Pubitemid 41728049)
13. Coppieters KT, Wiberg A, Von Herrath MG. Viral infections and molecular mimicry in type 1 diabetes. APMIS 2012; 120:941-949.
14. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21:335-376. (Pubitemid 37174535)
15. Mitsias DI, Kapsogeorgou EK, Moutsopoulos HM. The role of epithelial cells in the initiation and perpetuation of autoimmune lesions: lessons from Sjogren's syndrome (autoimmune epithelitis). Lupus 2006; 15:255-261. (Pubitemid 43828800)
16. Yao Y, Liu Z, Jallal B, et al. Type I interferons in Sjogren's syndrome. Autoimmun Rev 2013; 12:558-566.
17. Zheng L, Zhang Z, Yu C, et al. Association between IFN-alpha and primary Sjogren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 107:e12-e18.
18. Emamian ES, Leon JM, Lessard CJ, et al. Peripheral blood gene expression profiling in Sjogren's syndrome. Genes Immun 2009; 10:285-296.
19. Ronnblom L, Eloranta M-L. The interferon signature in autoimmune diseases. Curr Opin 2013; 25:248-253.
20. Borden EC, Sen GC, Uze G, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007; 6:975-990. (Pubitemid 350201788)
21. Ronnblom L, Alm GV. A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med 2001; 194:F59-F63. (Pubitemid 34028649)
22. Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999; 284:1835-1837.
23. Gaston JS, Rowe M, Bacon P. Sjogren's syndrome after infection by Epstein- Barr virus. J Rheumatol 1990; 17:558-561. (Pubitemid 20152213)
24. Horiuchi M, Yamano S, Inoue H, et al. Possible involvement of IL-12 expression by Epstein-Barr virus in Sjogren syndrome. J Clin Pathol 1999; 52:833-837. (Pubitemid 29524946)
25. Mariette X, Gozlan J, Clerc D, et al. Detection of Epstein-Barr virus DNA by in situ hybridization and polymerase chain reaction in salivary gland biopsy specimens from patients with Sjogren's syndrome. Am J Med 1991; 90:286-294.
26. Fox RI, Luppi M, Kang HI, et al. Reactivation of Epstein-Barr virus in Sjogren's syndrome. Springer Semin Immunopathol 1991; 13:217-231.
27. Inoue H, Mishima K, Yamamoto-Yoshida S, et al. Aryl hydrocarbon receptormediated induction of EBV reactivation as a risk factor for Sjogren's syndrome. J Immunol 2012; 188:4654-4662.
28. Tateishi M, Saito I, Yamamoto K, et al. Spontaneous production of Epstein- Barr virus by B lymphoblastoid cell lines obtained from patients with Sjogren's syndrome: possible involvement of a novel strain of Epstein-Barr virus in disease pathogenesis. Arthritis Rheum 1993; 36:827-835. (Pubitemid 23175626)
29. Vaughan JH, Valbracht JR, Nguyen MD, et al. Epstein-Barr virus-induced autoimmune responses. I. Immunoglobulin M autoantibodies to proteins mimicking and not mimicking Epstein-Barr virus nuclear antigen-1. J Clin Invest 1995; 95:1306-1315.
30. Soshilov A, Denison MS. Ligand displaces heat shock protein 90 from overlapping binding sites within the aryl hydrocarbon receptor ligand-binding domain. J Biol Chem 2011; 286:35275-35282.
31. Stejskalova L, Dvorak Z, Pavek P. Endogenous and exogenous ligands of aryl hydrocarbon receptor: current state of art. Curr Drug Metab 2011; 12:198-212.
32. Simones T, Shepherd DM. Consequences of AhR activation in steady-state dendritic cells. Toxicol Sci 2011; 119:293-307.
33. Jin G-B, Moore AJ, Head JL, et al. Aryl hydrocarbon receptor activation reduces dendritic cell function during influenza virus infection. Toxicol Sci 2010; 116:514-522.
34. Quintana FJ, Basso AS, Iglesias AH, et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008; 453:65-71. (Pubitemid 351630328)
35. Funatake CJ, Marshall NB, Steppan LB, et al. Cutting edge: activation of the aryl hydrocarbon receptor by 2,3,7,8-tetrachlorodibenzo-p-dioxin generates a population of CD4p CD25p cells with characteristics of regulatory T cells. J Immunol 2005; 175:4184-4188. (Pubitemid 41361950)
36. Allan LL, Sherr DH. Constitutive activation and environmental chemical induction of the aryl hydrocarbon receptor/transcription factor in activated human B lymphocytes. Mol Pharmacol 2005; 67:1740-1750. (Pubitemid 40594175)
37. Lu H, Crawford RB, Kaplan BLF, et al. 2,3,7,8-Tetrachlorodibenzo-p- dioxinmediated disruption of the CD40 ligand-induced activation of primary human B cells. Toxicol Appl Pharmacol 2011; 255:251-260.
38. Veldhoen M, Hirota K, Westendorf AM, et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 2008; 453:106-109. (Pubitemid 351630329)
39. Veldhoen M, Duarte JH. The aryl hydrocarbon receptor: fine-tuning the immune-response. Curr Opin Immunol 2010; 22:747-752.
40. Patel RD, Murray IA, Flaveny CA, et al. Ah receptor represses acute-phase response gene expression without binding to its cognate response element. Lab Invest 2009; 89:695-707.
41. Barzilai O, Sherer Y, Ram M, et al. Epstein-Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? A preliminary report. Ann N Y Acad Sci 2007; 1108:567-577. (Pubitemid 47528770)
42. Ohyama Y, Carroll VA, Deshmukh U, et al. Severe focal sialadenitis and dacryoadenitis in NZM2328 mice induced by MCMV: a novel model for human Sjogren's syndrome. J Immunol 2006; 177:7391-7397. (Pubitemid 44715109)
43. Cardin RD, Schaefer GC, Allen JR, et al. The M33 chemokine receptor homolog of murine cytomegalovirus exhibits a differential tissue-specific role during in vivo replication and latency. J Virol 2009; 83:7590-7601.
44. Case R, Sharp E, Benned-Jensen T, et al. Functional analysis of the murine cytomegalovirus chemokine receptor homologue M33: ablation of constitutive signaling is associated with an attenuated phenotype in vivo. J Virol 2008; 82:1884-1898. (Pubitemid 351222436)
45. Davis-Poynter NJ, Lynch DM, Vally H, et al. Identification and characterization of a G protein-coupled receptor homolog encoded by murine cytomegalovirus. J Virol 1997; 71:1521-1529. (Pubitemid 27030328)
46. Farrell HE, Abraham AM, Cardin RD, et al. Identification of common mechanisms by which human and mouse cytomegalovirus seven transmembrane receptor homologues contribute to in vivo phenotypes in a mouse model. J Virol 2013; 87:4112-4117.
47. De Stefano R, Manganelli S, Frati E, et al. No association between human parvovirus B19 infection and Sjogren's syndrome. Ann Rheum Dis 2003; 62:86-87. (Pubitemid 36005807)
48. De Re V, De Vita S, Battistella V, et al. Absence of human parvovirus B19 DNA in myoepithelial sialadenitis of primary Sjogren's syndrome. Ann Rheum Dis 2002; 61:855-856.
49. Ramos-Casals M, Cervera R, García-Carrasco M, et al. Cytopenia and past human parvovirus B19 infection in patients with primary Sjogren's syndrome. Semin Arthritis Rheum 2000; 29:373-378. (Pubitemid 30413825)
50. Chen C-H, Yang P-M, Huang G-T, et al. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007; 106:148-155. (Pubitemid 46390505)
51. Watanabe K, Ohkubo Y, Funahashi Y, et al. An investigation on rheumatoid factor of different immunoglobulin classes in hepatitis B virus carriers. Clin Rheumatol 1991; 10:31-37.
52. Marcos M, Alvarez F, Brito-Zerón P, et al. Chronic hepatitis B virus infection in Sjogren's syndrome: prevalence and clinical significance in 603 patients. Autoimmun Rev 2009; 8:616-620.
53. Ramos-Casals M, García-Carrasco M, Cervera R, et al. Hepatitis C virus infection mimicking primary Sjogren syndrome: a clinical and immunologic description of 35 cases. Medicine 2001; 80:1-8. (Pubitemid 32066374)
54. Smyth CM, McKiernan SM, Hagan R, et al. Chronic hepatitis C infection and Sicca syndrome: a clear association with HLA DQB1-02. Eur JGastroenterol Hepatol 2007; 19:493-498. (Pubitemid 46725756)
55. Loustaud-Ratti V, Riche A, Liozon E, et al. Prevalence and characteristics of Sjogren's syndrome or Sicca syndrome in chronic hepatitis C virus infection: a prospective study. J Rheumatol 2001; 28:2245-2251. (Pubitemid 32947870)
56. Scott CA, Avellini C, Desinan L, et al. Chronic lymphocytic sialoadenitis in HCV-related chronic liver disease: comparison of Sjogren's syndrome. Histopathology 1997; 30:41-48. (Pubitemid 27072447)
57. Freni MA, Artuso D, Gerken G, et al. Focal lymphocytic aggregates in chronic hepatitis C: occurrence, immunohistochemical characterization, and relation to markers of autoimmunity. Hepatology 1995; 22:389-394.
58. Vitali C, Sciuto M, Neri R, et al. Antihepatitis C virus antibodies in primary Sjogren's syndrome: false positive results are related to hyper-gamma-globulinaemia. Clin Exp Rheumatol 1992; 10:103-104.
59. Nagao Y, Hanada S, Shishido S, et al. Incidence of Sjogren's syndrome in Japanese patients with hepatitis C virus infection. J Gastroenterol Hepatol 2003; 18:258-266. (Pubitemid 36513154)
60. Carrozzo M. Oral diseases associated with hepatitis C virus infection. Part 1. Sialadenitis and salivary glands lymphoma. Oral Dis 2008; 14:123-130. (Pubitemid 351301053)
61. Ramos-Casals M, Loustaud-Ratti V, De Vita S, et al. Sjogren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases. Medicine 2005; 84:81-89. (Pubitemid 40418636)
62. Toussirot E, Le HuédéG, Mougin C, et al. Presence of hepatitis Cvirus RNA in the salivary glands of patients with Sjogren's syndrome and hepatitis C virus infection. J Rheumatol 2002; 29:2382-2385. (Pubitemid 35266030)
63. Arrieta JJ, Rodríguez-Iñigo E, Ortiz-Movilla N, et al. In situ detection of hepatitis C virus RNA in salivary glands. Am J Pathol 2001; 158:259-264. (Pubitemid 32096491)
64. Grossmann Sde M, Teixeira R, Oliveira GC, et al. Xerostomia, hyposalivation and sialadenitis in patients with chronic hepatitis C are not associated with the detection of HCV RNA in saliva or salivary glands. J Clin Pathol 2010; 63:1002-1007.
65. Koike K, Moriya K, Ishibashi K, et al. Sialadenitis histologically resembling Sjogren syndrome in mice transgenic for hepatitis C virus envelope genes. Proc Natl Acad Sci USA 1997; 94:233-236.
66. Rosa D, Saletti G, De Gregorio E, et al. Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci USA 2005; 102:18544-18549. (Pubitemid 43011262)
67. Machida K, Cheng KT-H, Pavio N, et al. Hepatitis C virus E2-CD81 interaction induces hypermutation of the immunoglobulin gene in B cells. J Virol 2005; 79:8079-8089. (Pubitemid 40853511)
68. Roughan JE, Reardon KM, Cogburn KE, et al. Chronic hepatitis C virus infection breaks tolerance and drives polyclonal expansion of autoreactive B cells. Clin Vacc Immunol 2012; 19:1027-1037.
69. Meltzer M, Franklin EC. Cryoglobulinemia - a study of twenty-nine patients. I. IgG and IgM cryoglobulins and factors affecting cryoprecipitability. Am J Med 1966; 40:828-836.
70. Meltzer M, Franklin EC, Elias K, et al. Cryoglobulinemia - a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med 1966; 40:837-856.
71. Himoto T, Masaki T. Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection. Clin Dev Immunol 2012; 2012: 871401.
72. Ramos-Casals M, Font J. Extrahepatic manifestations in patients with chronic hepatitis C virus infection. Curr Opin Rheumatol 2005; 17:447-455. (Pubitemid 41058405)
73. Ramos-Casals M, La Civita L, De Vita S, et al. Characterization of B cell lymphoma in patients with Sjogren's syndrome and hepatitis C virus infection. Arthritis Rheum 2007; 57:161-170.
74. De Vita S, Quartuccio L, Salvin S, et al. Cryoglobulinaemia related to Sjogren's syndrome or HCV infection: differences based on the pattern of bone marrow involvement, lymphoma evolution and laboratory tests after parotidectomy. Rheumatology 2012; 51:627-633.
75. Ramos-Casals M, García-Carrasco M, Cervera R, et al. Th1/Th2 cytokine imbalance in patients with Sjogren syndrome secondary to hepatitis C virus infection. Semin Arthritis Rheum 2002; 32:56-63. (Pubitemid 35001165)
76. Jorgensen C, Legouffe MC, Perney P, et al. Sicca syndrome associated with hepatitis C virus infection. Arthritis Rheum 1996; 39:1166-1171. (Pubitemid 26240230)
77. Ramos-Casals M, García-Carrasco M, Brito Zerón MP, et al. Viral etiopathogenesis of Sjogren's syndrome: role of the hepatitis C virus. Autoimmun Rev 2002; 1:238-243. (Pubitemid 38340259)
78. Bockle BC, Baltaci M, Ratzinger G, et al. Hepatitis C and autoimmunity: a therapeutic challenge. J Intern Med 2012; 271:104-106.
79. Ulbricht KU, Schmidt RE, Witte T. Antibodies against alpha-fodrin in Sjogren's syndrome. Autoimmun Rev 2003; 2:109-113. (Pubitemid 37443863)
80. Potthoff A, Witte T, Rifai K, et al. Prevalence of alpha-fodrin antibodies in patients with chronic hepatitis C infection and Sjogren syndrome. Scand J Gastroenterol 2009; 44:994-1003.
81. Nordmark G, Rorsman F, Ronnblom L, et al. Autoantibodies to alpha-fodrin in primary Sjogren's syndrome and SLE detected by an in vitro transcription and translation assay. Clin Exp Rheumatol 2003; 21:49-56. (Pubitemid 36267531)
82. Brito-Zerón P, Retamozo S, Gandía M, et al. Monoclonal gammopathy related to Sjogren syndrome: a key marker of disease prognosis and outcomes. J Autoimmun 2012; 39:43-48.
83. Doffoel-Hantz V, Loustaud-Ratti V, Ramos-Casals M, et al. Evolution of Sjogren syndrome associated with hepatitis C virus when chronic hepatitis C is treated by interferon or the association of interferon and ribavirin. Rev Méd Interne 2005; 26:88-94. (Pubitemid 40260512)
84. Triantafyllopoulou A, Tapinos N, Moutsopoulos HM. Evidence for Coxsackie virus infection in primary Sjogren's syndrome. Arthritis Rheum 2004; 50:2897-2902. (Pubitemid 39209528)
85. Agirre A, Barco A, Carrasco L, et al. Viroporin-mediated membrane permeabilization: pore formation by nonstructural poliovirus 2B protein. J Biol Chem 2002; 277:40434-40441. (Pubitemid 35215619)
86. Stathopoulou EA, Routsias JG, Stea EA, et al. Cross-reaction between antibodies to the major epitope of Ro60 kD autoantigen and a homologous peptide of Coxsackie virus 2B protein. Clin Exp Immunol 2005; 141:148-154. (Pubitemid 40904652)
87. De ThéG, Bomford R. An HTLV-I vaccine: why, how, for whom? AIDS Res Hum Retroviruses 1993; 9:381-386.
88. Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol 2012; 3:; 388.
89. Satake M, Yamaguchi K, Tadokoro K. Current prevalence of HTLV-1 in Japan as determined by screening of blood donors. J Med Virol 2012; 84:327-335.
90. Ohyama Y, Nakamura S, Hara H, et al. Accumulation of human T lymphotropic virus type I-infected T cells in the salivary glands of patients with human T lymphotropic virus type I-associated Sjogren's syndrome. Arthritis Rheum 1998; 41:1972-1978. (Pubitemid 28506687)
91. Eguchi K, Matsuoka N, Ida H, et al. Primary Sjogren's syndrome with antibodies to HTLV-I: clinical and laboratory features. Ann Rheum Dis 1992; 51:769-776.
92. Terada K, Katamine S, Eguchi K, et al. Prevalence of serum and salivary antibodies to HTLV-1 in Sjogren's syndrome. Lancet 1994; 344:1116-1119.
93. Bogenberger JM, Laybourn PJ. Human T lymphotropic virus type 1 protein Tax reduces histone levels. Retrovirology 2008; 5:9.
94. Coulderc LJ, Desgranges C, Coste J, et al. Antibodies to HTLV-I in Sjogren's syndrome. Lancet 1995; 345:72.
95. Sasaki M, Nakamura S, Ohyama Y, et al. Accumulation of common T cell clonotypes in the salivary glands of patients with human T lymphotropic virus type I-associated and idiopathic Sjogren's syndrome. J Immunol 2000; 164:2823-2831. (Pubitemid 30115518)